StimCardio raises $30M to take atrial fibrillation treatment out of the hospital
What's the deal? StimCardio, a Los Angeles clinical-stage medical device company, has closed an oversubscribed $30 million Series A led by Metis Medtech, the family office of John Slump, with participation from Catalyst Health VenturesDealroom has a profile for this one. Try Dealroom →, corporate strategic investors, and others. The money funds a pivotal study of Rhyvive, a wrist-worn wearable for atrial fibrillation (AF), and preparation of a De Novo submission to the US Food and Drug Administration.
What's the endgame? Rhyvive delivers non-invasive median nerve stimulation through a closed-loop system that pairs physiological sensing with neuromodulation. Designed as an adjunct to catheter ablation, it aims to extend treatment from the procedure room into the patient's home.
Why now? Roughly 59 million people worldwide live with AF, according to a 2025 analysis in the Journal of the American College of Cardiology . Despite advances in catheter ablation, 30% to 40% of patients experience recurrent AF after a first procedure — the gap StimCardio is targeting.
What they're saying: "Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology," said chief executive officer Amir Soltanianzadeh. Slump, a StimCardio board member, said the company offers "an entirely different approach with a non-invasive wearable that we believe will redefine the treatment paradigm."
What could go wrong? The funding is not evidence that wearable neuromodulation works. Its significance hinges on the planned pivotal study delivering rigorous clinical validation and a credible regulatory path.
The signal: The raise is an early-stage bet on a non-invasive alternative in a field dominated by catheter-based tools. It follows continued AF investment, including MedtronicDealroom has a profile for this one. Try Dealroom →'s July lead of CoreMap's $37 million Series C for ablation mapping and Kardium's financing for pulsed-field ablation — a sign of investor interest across the AF treatment pathway.
Read more: pr.lakeoconeebreeze.net
Image credit: Generated with Gemini
